<DOC>
	<DOCNO>NCT01852409</DOCNO>
	<brief_summary>Malignant ascites often profound impact quality life cancer patient . Current treatment , include dietary , medical , procedural often temporary unsatisfactory option patient approach end life . Intraperitoneal bevacizumab palliation malignant ascites might novel choice refractory malignant ascites .</brief_summary>
	<brief_title>Phase I Trial Intraperitoneal Bevacizumab Refractory Malignant Ascites</brief_title>
	<detailed_description />
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . Signed informed consent form ; 2 . Histologically cytologically confirm nonsquamous cell carcinoma，including colorectal cancer , gastric cancer , esophageal cancer , pancreatic cancer , bile duct cancer , ovarian cancer , peritoneal primary tumor ; Ascites diagnose ultrasound CT confirm malignant ascites cytology ; 3. fail standard systemic therapy / appropriate treatment treatment malignant ascites 4 . Age 1870 year ; 5 . Performance Status Eastern Cooperative Oncology Group ( ECOG ) ≤2 ; 6 . Life expectancy least 8 week ; 1. systematic anticancer therapy , include chemotherapy ( intraperitoneal chemotherapy ) , radiation therapy , immunotherapy , biological hormone therapy perform within 2 week ; 2. tyrosine kinase inhibitor monoclonal antibody antivascular endothelial growth factor ( VEGF ) perform within 4 week ; 3 . Laboratory test : Absolute neutrophil count &lt; 1.0x109/L , Platelet count &lt; 75x 109/L , Hemoglobin &lt; 8g/dl , PTINR≥1.5 time upper limit normal ( ULN ) ; Bilirubin≥2 x ULN , AST ALT≥2.5 time ULN ( liver metastasis ) , ≥5 time ULN ( liver metastasis ) Creatinine≥1.5 time ULN calculate creatinine clearance , use CockcroftGault formula , &lt; 40 mL/min ; 4. uncontrolled hypertension : systolic pressure ≥160 mmHg , diastolic pressure≥100mmHg 5 . Known history severe heart disease , uncontrolled symptomatic angina , congestive heart failure , clinically significant arrhythmia , myocardial infarction within six month ; 6. active ( severe uncontrolled ) bleeding ( hemorrhage within 3 month &gt; 30 ml ) , hemoptysis ( fresh blood , 4 week &gt; 5 ml ) , bloody ascites 7. thrombosis , tumor thrombus event ( include arterial/venous thrombosis , tumor thrombosis , pulmonary embolism , transient ischemic attack ) within 12 month ; 8 . Portal hypertensive disease severe liver disease , include various type cirrhosis , obstructive jaundice ; 9. concurrent gastrointestinal obstruction , peptic ulcer , Crohn 's disease , ulcerative colitis gastrointestinal disease accord investigator ' determination may cause gastrointestinal bleeding perforation ; 10. concurrent severe respiratory disease , chronic therapy oxygen corticosteroid , chronic obstructive pulmonary disease , interstitial lung disease , etc . 11 . Unresolved unstable , serious toxicity prior cancer treatment ( toxicity great grade 2 recovered surgery ; 12 . Symptomatic brain metastasis ; 13 . Uncontrolled systemic disease , infection , unstable diabetes mellitus , etc ; 14 . Active infection HIV、HBV、HCV； 15 . Major surgery within 4 week start study treatment , without complete recovery . 16 . Pregnant lactate women.Negative serum pregnancy test ( For woman childbearing potential ) ; Fertile patient must use effective contraception . 17 . Dementia , alter mental status , psychiatric condition would prevent understand render ICF ; 18 . Received investigational drug treatment within 4 week start study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>refractory malignant ascites</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>intraperitoneal</keyword>
	<keyword>phase I</keyword>
</DOC>